Who founded Praeventix?

Praeventix was founded by Douglas Pippin in 2022.

How much funding has Praeventix raised?

Praeventix has disclosed $14.1M raised across 3 rounds.

Where is Praeventix headquartered?

Praeventix is headquartered in Exton, US.

Praeventix

Exton, US · Founded 2022 · Delaware corporation

Praeventix is an early-stage biopharmaceutical company developing serotonergic (5-HT7 receptor) therapeutics, with a lead topical candidate PRA-523 aimed at treating chronic pruritus in conditions such as atopic dermatitis. It is also researching 5-HT7 modulators for inflammatory bowel disease and cocaine use disorder.

Biotech Digital Health

Founders & leadership

Praeventix was founded in 2022 by Douglas Pippin.

Douglas PippinPresident & Founder, PI

Heidi KempinskiExecutive

Leon O. Moulder, Jr.Executive

KempinskiCEO

MoulderExecutive Chair

Board

Robert S. HankinBoard director

Leonard O. Moulder, Jr.Board director

Reported raises · per SEC filings

Form D private placements

$14.1M disclosed across 3 rounds · 2022–2026

▶$3MraisedFeb 2026 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Leon O. MoulderDirector
Douglas A. Pippin, PhDExecutive Officer, Director
Heidi KempinskiExecutive Officer, Director
Robert S. HankinDirector

Offering amount: $5M
Amount sold: $3M
First sale: Feb 2026
Incorporated: Corporation, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$6.8MraisedMay 2025 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Heidi KempinskiExecutive Officer, Director
Douglas A. PippinExecutive Officer, Director
Robert S. HankinDirector
Leonard O. Moulder, Jr.Director

Offering amount: $6.8M
Amount sold: $6.8M
First sale: May 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.3MraisedMay 2024 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Douglas A. PippinExecutive Officer, Director
Leon O. Moulder, Jr.Director

Offering amount: $4.3M
Amount sold: $4.3M
Proceeds to insiders: $1.3M
First sale: Oct 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Bioworld17 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Praeventix for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Praeventix do?: Praeventix is an early-stage biopharmaceutical company developing serotonergic (5-HT7 receptor) therapeutics, with a lead topical candidate PRA-523 aimed at treating chronic pruritus in conditions such as atopic dermatitis. It is also researching 5-HT7 modulators for inflammatory bowel disease and cocaine use disorder.
Who founded Praeventix?: Praeventix was founded by Douglas Pippin in 2022.
How much funding has Praeventix raised?: Praeventix has disclosed $14.1M raised across 3 rounds.
Where is Praeventix headquartered?: Praeventix is headquartered in Exton, US.